Intraoperative Ultrasound-Guided Cryoablation of Renal Tumors

Publication
Article
OncologyONCOLOGY Vol 12 No 11
Volume 12
Issue 11

Renal cancer occurs in nearly 10 of every 100,000 people in the United States and in approximately 45 of every 100,000 of those over 65 years of age. Standard treatment is open surgery, often involving total removal of the tumor along with the kidney. However, a study in the September issue of the Journal of Ultrasound in Medicine reports that ultrasound-guided renal cryoablation is a feasible technique for treating renal malignancies while still preserving the renal parenchyma.

Renal cancer occurs in nearly 10 of every 100,000 people in the United States and in approximately 45 of every 100,000 of those over 65 years of age. Standard treatment is open surgery, often involving total removal of the tumor along with the kidney. However, a study in the September issue of the Journal of Ultrasound in Medicine reports that ultrasound-guided renal cryoablation is a feasible technique for treating renal malignancies while still preserving the renal parenchyma.

Sparing Renal Tissue

Harry G. Zegel, MD, and coauthors from theAllegheny University Hospitals in Pennsylvania and Urology Specialists of Coastal Georgia write, "Recent advances in cross-sectional imaging (ultrasound, MRI, CT) have led to increased detection of small, asymptomatic renal tumors. Also, in selected cases, patients undergoing partial nephrectomy have been reported to have rates of survival similar to those of patients undergoing radical nephrectomy. This has led some physicians to question the need for radical nephrectomy in patients with small lesions. While partial nephrectomy spares the maximal amount of functioning renal tissue, and often eliminates or postpones the need for dialysis, this technique is associated with risks. Hence, better kidney tissue-sparing techniques may be of benefit in selected patients."

The study examined the feasibility of using ultrasound-guided cryosurgery to treat selected patients with renal malignancy by studying the technique in six patients with renal tumors.

Benefits of Intraoperative Ultrasonography

In the study, intraoperative ultrasonography accurately delineated tumor size, cryoprobe placement, and depth of freezing in all patients. In addition, intraoperative ultrasonography identified a total of nine additional lesions in three patients that had not been detected by preoperative imaging. The patients have been followed with clinical and laboratory assessments, as well as MRI or CT imaging, and all were tumor-free 3 to 22 months, postoperatively.

In conclusion, the authors write, "we conclude that cryoablation with intraoperative ultrasonographic guidance is a promising new technique for treating renal masses while preserving renal parenchyma and function. Long-term follow-up in a larger series of patients with biopsy-proved lesions is necessary to determine the true efficacy and safety of this procedure."

Recent Videos
One of the largest obstacles to tackle in the kidney cancer landscape will be translating the research on rare kidney cancer subtypes into clinical trials.
Zanzalitinib exhibited favorable data when evaluated alone or in combination with anti-PD-1 immune checkpoint inhibition in phase 1 RCC trials.
The investigational agent exhibited superior efficacy vs pembrolizumab in patients with lung cancer, suggesting potential efficacy in kidney cancer.
“As a community, if we’re looking to help enroll and advocate for patients with rare [kidney cancers], we need to be aware of what is out there,” said A. Ari Hakimi, MD.
Treatment with the dual inhibitor displayed a short half-life and a manageable toxicity profile in patients with clear cell renal cell carcinoma.
The annual Kidney Cancer Research Summit was born from congressional funding for kidney cancer research, according to KidneyCAN president Bryan Lewis.
Combining renal vaccines with immune therapy may better target tumor cells while limiting harm to healthy tissue, according to David A. Braun, MD, PhD.
Improving data collection and biomarker development across institutions may represent areas of expansion in kidney cancer research.
KIM-1 is a biomarker in the blood that may help noninvasively detect kidney cancer, according to Wenxin (Vincent) Xu, MD.
A phase 0 trial is seeking to assess the feasibility of aiding anti-cancer cells with cytokines to restore their function.
Related Content